eviplera
gilead sciences pty ltd - tenofovir disoproxil fumarate; rilpivirine hydrochloride; emtricitabine -
sprycel
bristol-myers squibb australia pty ltd - dasatinib -
aggrastat
pharmacy retailing (nz) ltd t/a healthcare logistics - tirofiban hydrochloride monohydrate 0.281 mg/ml equivalent to 0.25 mg/ml tirofiban; - concentrate for infusion - 0.25 mg/ml - active: tirofiban hydrochloride monohydrate 0.281 mg/ml equivalent to 0.25 mg/ml tirofiban excipient: citric acid hydrochloric acid sodium chloride sodium citrate dihydrate sodium hydroxide water for injection
eviplera
gilead sciences (nz) - emtricitabine 200mg; ; ; ; rilpivirine hydrochloride 27.5mg equivalent to rilpivirine free base 25 mg; ; tenofovir disoproxil fumarate 300mg; ; ; - film coated tablet - active: emtricitabine 200mg rilpivirine hydrochloride 27.5mg equivalent to rilpivirine free base 25 mg tenofovir disoproxil fumarate 300mg excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry polysorbate 20 povidone pregelatinised maize starch purified water - eviplera is indicated for the treatment of hiv infection in treatment-na?ve adult patients with plasma hiv-1 rna less than or equal to 100,000 copies/ml at the start of therapy. eviplera is also indicated in certain virologically-suppressed (hiv-1 rna <50 copies/ml) adult patients on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen (see clinical trials). patients must not have a history of resistance to any of the components of eviplera (tenofovir df, emtricitabine or rilpivirine).
sprycel
bristol-myers squibb (nz) limited - dasatinib 100mg; - film coated tablet - 100 mg - active: dasatinib 100mg excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-18177-a - · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with newly diagnosed chronic myeloid leukaemia (cml). · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. · sprycel® (dasatinib) is indicated for the treatment of paediatric patients with philadelphia chromosome positive chronic myeloid leukaemia (cml) in the chronic phase
sprycel
bristol-myers squibb (nz) limited - dasatinib 20mg; - film coated tablet - 20 mg - active: dasatinib 20mg excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-18177-a - · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with newly diagnosed chronic myeloid leukaemia (cml). · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. · sprycel® (dasatinib) is indicated for the treatment of paediatric patients with philadelphia chromosome positive chronic myeloid leukaemia (cml) in the chronic phase
sprycel
bristol-myers squibb (nz) limited - dasatinib 50mg; - film coated tablet - 50 mg - active: dasatinib 50mg excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-18177-a - · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with newly diagnosed chronic myeloid leukaemia (cml). · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. · sprycel® (dasatinib) is indicated for the treatment of paediatric patients with philadelphia chromosome positive chronic myeloid leukaemia (cml) in the chronic phase
sprycel
bristol-myers squibb (nz) limited - dasatinib 70mg; - film coated tablet - 70 mg - active: dasatinib 70mg excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-18177-a - · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with newly diagnosed chronic myeloid leukaemia (cml). · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. · sprycel® (dasatinib) is indicated for the treatment of paediatric patients with philadelphia chromosome positive chronic myeloid leukaemia (cml) in the chronic phase
sprycel dasatinib 100 mg tablet bottle
bristol-myers squibb australia pty ltd - dasatinib, quantity: 100 mg - tablet, film coated - excipient ingredients: hyprolose; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; lactose monohydrate; titanium dioxide; hypromellose; macrogol 400 - sprycel is indicated for the treatment of adults aged 18 years or over with: - newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase. - chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukameia with resistance or intolerance to prior therapy including imatinib. - newly diagnosed philadelphia chromosome positive acute lymphoblastic leukameia integrated with chemotherapy. - philadelphia chromosome positive acute lymphoblastic leukamia with resistance or intolerance to prior therapy.,sprycel is indicated for the treatment of paediatric patients with: - ph+ cml in the chronic phase. - newly diagnosed ph+ all in combination with chemotherapy.
sprycel dasatinib 70 mg tablet bottle
bristol-myers squibb australia pty ltd - dasatinib, quantity: 70 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; hyprolose; lactose monohydrate; titanium dioxide; hypromellose; macrogol 400 - sprycel is indicated for the treatment of adults aged 18 years or over with: - newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase. - chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukameia with resistance or intolerance to prior therapy including imatinib. - newly diagnosed philadelphia chromosome positive acute lymphoblastic leukameia integrated with chemotherapy. - philadelphia chromosome positive acute lymphoblastic leukamia with resistance or intolerance to prior therapy.,sprycel is indicated for the treatment of paediatric patients with: - ph+ cml in the chronic phase. - newly diagnosed ph+ all in combination with chemotherapy.